GCAC
BCLI

Guardian Capital Advisors (Canada)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Guardian Capital Advisors (Canada)’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-667
Closed -$41K – 162
2017
Q1 		$41K Buy
+667
New +$34.7K 0.01% 166
2016
Q4 		– Sell
-667
Closed -$24K – 169
2016
Q3 		$24K Hold
667
– – ﹤0.01% 160
2016
Q2 		$25K Hold
667
– – ﹤0.01% 161
2016
Q1 		$23K Buy
+667
New +$24.5K ﹤0.01% 165

Other funds holding BCLI

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Guardian Capital Advisors (Canada)'s BCLI Position: Q2 2017 in Review

Guardian Capital Advisors (Canada) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2017, closing a stake of 667 shares — an estimated $41K sold.

Guardian Capital Advisors (Canada) first reported a position in BCLI in Q1 2016 and held it in 4 quarters. The position peaked at $41K in Q1 2017. 26 funds tracked by Wall St. Rank hold BCLI as of Q2 2017.

  • Guardian Capital Advisors (Canada) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2017 after selling out during the quarter.
  • Guardian Capital Advisors (Canada) sold 667 BRAINSTORM CELL THERAPUTC shares in Q2 2017, an estimated $41K.
  • Guardian Capital Advisors (Canada) first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 4 quarters.
  • Guardian Capital Advisors (Canada)'s BRAINSTORM CELL THERAPUTC position peaked at $41K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2017.

Based on Guardian Capital Advisors (Canada)'s 13F filing for Q2 2017, filed 14 Aug 2017.